Amgen Inc. (NASDAQ:AMGN) Shares Bought by Williams Jones Wealth Management LLC.

Williams Jones Wealth Management LLC. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 114,404 shares of the medical research company's stock after purchasing an additional 5,937 shares during the period. Williams Jones Wealth Management LLC.'s holdings in Amgen were worth $29,818,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Centricity Wealth Management LLC purchased a new position in Amgen in the fourth quarter valued at about $25,000. Ritter Daniher Financial Advisory LLC DE grew its holdings in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares during the period. Synergy Investment Management LLC purchased a new position in Amgen in the 4th quarter valued at approximately $34,000. Atala Financial Inc acquired a new position in Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC purchased a new stake in Amgen during the fourth quarter worth $36,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In related news, EVP David M. Reese sold 8,711 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total value of $2,554,239.42. Following the transaction, the executive vice president now owns 62,147 shares in the company, valued at approximately $18,222,743.34. This trade represents a 12.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.76% of the company's stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research analyst reports. Erste Group Bank cut Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. UBS Group reaffirmed a "neutral" rating and issued a $315.00 price target (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Mizuho increased their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald started coverage on Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of "Hold" and an average price target of $310.18.

Amgen Stock Performance

Shares of AMGN stock opened at $275.85 on Tuesday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market capitalization of $148.33 billion, a price-to-earnings ratio of 36.54, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a 50 day moving average price of $290.27 and a 200 day moving average price of $287.56.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.96 EPS. Sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.45%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is currently 86.86%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.